Delving into the Latest Updates on Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd with Synapse

Overview

Basic Info

Introduction

Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd. was established in the year 2013, evolving from a municipal engineering and technology research center authorized by the Shanghai Municipal Science and Technology Commission. This entity has been structured as a high-tech enterprise.

Tags

Neoplasms

Digestive System Disorders

Endocrinology and Metabolic Disease

CAR-T

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	9
Hemic and Lymphatic Diseases	3
Immune System Diseases	3
Endocrinology and Metabolic Disease	3
Nervous System Diseases	1

Top 5 Drug Type	Count

CAR-T	8
Autologous CAR-T	1

Top 5 Target	Count

PD-1(Programmed cell death protein 1)	1

主要目的： Ia期：评估aPD1-MSLN-CAR T细胞用于标准治疗失败间皮素阳性的晚期间皮瘤、宫颈癌等恶性实体瘤受试者的安全性和耐受性，确定RP2D。 Ib期：评估aPD1-MSLN-CAR T细胞用于Ib期-队列1和队列2受试者的安全性。次要目的： Ia期：初步评价aPD1-MSLN-CAR T细胞用于治疗间皮素阳性晚期恶性实体瘤受试者的有效性，包括客观缓解率（ORR）、疾病控制率（DCR）、总生存期（OS）、无进展生存期（PFS）、缓解持续时间（DOR）。 Ib期：初步评价aPD1-MSLN-CAR T细胞用于治疗Ib期-队列1和队列2受试者的有效性，包括客观缓解率（ORR）、疾病控制率（DCR）、总生存期（OS）、无进展生存期（PFS）、缓解持续时间（DOR）。

[Translation]

Primary objectives: Phase Ia: To evaluate the safety and tolerability of aPD1-MSLN-CAR T cells for subjects with advanced mesothelin-positive mesothelioma, cervical cancer and other malignant solid tumors who have failed standard treatment, and determine RP2D. Phase Ib: To evaluate the safety of aPD1-MSLN-CAR T cells for subjects in Phase Ib-Cohort 1 and Cohort 2. Secondary objectives: Phase Ia: To preliminarily evaluate the effectiveness of aPD1-MSLN-CAR T cells for the treatment of subjects with advanced mesothelin-positive malignant solid tumors, including objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and duration of response (DOR). Phase Ib: To preliminarily evaluate the effectiveness of aPD1-MSLN-CAR T cells for the treatment of subjects in Phase Ib-Cohort 1 and Cohort 2, including objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and duration of response (DOR).

Start Date-

Sponsor / Collaborator

Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd

100 Clinical Results associated with Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd

Login to view more data

100 Deals associated with Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd

Login to view more data

100 Translational Medicine associated with Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

8

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Autocrine PD1 antibody targets mesothelin chimeric antigen receptor T cells (Shanghai Cell Therapy Group) ( PD-1 )	Mesothelin positive Neoplasms More	Phase 1
BZDS-1904	Glioma More	Preclinical
BZDS-2001	Acute Lymphoblastic Leukemia More	Preclinical
BZDS-1903	Colonic Cancer More	Preclinical
BZDS-1902	Colonic Cancer More	Preclinical